Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChemoID-Guided Chemotherapy vs Physician Choice in Recurrent Ovarian Cancer
NCT03632798Phase 3Withdrawn
- Sponsor
- Cordgenics LLC
- Start
- Aug 2018
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Cordgenics LLC. Primary endpoint: Progression Free Survival at 36 months. Planned start Aug 2018; status: withdrawn.
Beyond the preview
Go deeper on NCT03632798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632798.